This paper looks to try and understand infusion reactions from Gazyvaro (obinutuzumab)... study is on going...
As external validation was limited and models were derived using a single data set, these results will need to be corroborated with the generation of further patient data from ongoing clinical studies. The improvement in antibody technology realized by obinutuzumab can confer benefit to more patients if we can better understand how to predict, manage and prevent IRR. This is currently the subject of evaluation in ongoing clinical trials (NCT01905943 and NCT02336048) and these results may shed more light on how best to prevent this immunologic phenomenon.
Interesting that "Patients with higher baseline expression CD20 on their CLL cells were at greater risk for severe grade early IRR..." and "The resulting model was significant for the presence of trisomy 12 being associated with increased risk."
I read the paper twice and need to read it again--willing my brain to take it all in.
Thanks Sue...that was Dr. Sharman's quoted... thunder and lightening, but it is very true.
Photography gets me out everyday, so it is part of my on going treatment... I'm using video now to overcome some mobility and tremor difficulties I have... at 60 still images a second there is lots to choose from ... in a video 😄
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Cardiotoxicity in patients treated with acalabrutinib
